menu
    • menu

    Company profile for Zhejiang Jiuzhou Pharmaceutical

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    INTERMEDIATES

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is a medium-scale private enterprise, which focuses in the production of APIs. Our company grows out of Dongshan Chemical Factory which was founded in 1973. Under the direction of the President Mr. Hua Xuande, the staffs of Jiuzhou are fully obedience to the Jiuzhou spirit of “Unite, Progress, Strictness and Innovation". With the strict management for more than 30 years, Jiuzhou keep...
    Zhejiang Jiuzhou Pharmaceutical Co., Ltd. is a medium-scale private enterprise, which focuses in the production of APIs. Our company grows out of Dongshan Chemical Factory which was founded in 1973. Under the direction of the President Mr. Hua Xuande, the staffs of Jiuzhou are fully obedience to the Jiuzhou spirit of “Unite, Progress, Strictness and Innovation". With the strict management for more than 30 years, Jiuzhou keeps growing. Today, Jiuzhou Pharmaceutical has turned into a large-scale cooperate limited pharmaceutical enterprise covering an area of 300,000 sq. m., about 2000 employees.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Zhejiang Jiuzhou PharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    99 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.jiuzhoupharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI India

    Not Confirmed

    envelop Contact Supplier

    CPhI India

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    mic“Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    This week, SpeakPharma interviews Marie-Armelle Floc’h, Chief of Quality and Regulatory Affairs at HTL Biotechnology, a global leader in the development and the manufacturing of pharmaceutical-grade biopolymers headquartered in Javené, Brittany (France). Since 1992, HTL has pioneered the production of hyaluronic acid (HA) through proprietary biofermentation, achieving unmatched purity and consistency for applications in ophthalmology, dermatology and rheumatology. Floc’h highlights how HTL Biotechnology’s compelling portfolio of pharmaceutical-grade biopolymers is built on uncompromising quality standards. These standards have enabled the company to supply biopolymers for over 30 years without a single batch recall, firmly establishing its reputation for reliability and excellence. She also discusses the inauguration of HTL Biotechnology’s new sterile hyaluronic acid production unit — a major milestone that reinforces the company’s leadership in biopolymer manufacturing and enables the development of innovative formulations combining hyaluronic acid with thermo-sensitive active ingredients. This new capability opens the door to advanced biomedical applications where safety, stability and efficacy must be preserved without compromising the integrity of delicate molecules and which requires the highest quality standards. What distinguishes HTL Biotechnology’s biopolymer platforms in the market today? HTL Biotechnology has built its reputation on delivering pharmaceutical‑grade biopolymers (hyaluronic acid, polynucleotides and recombinant collagen) with unmatched purity and consistency. Since its founding in 1992, the company has focused on premium quality positioning. With more than 30 years of experience, HTL Biotechnology guarantees pharmaceutical-grade biopolymers of exceptional purity and exemplary consistency to our clients. We have had no batch recalls in 30 years, a record that underlines the rigor and reliability embedded in our processes. This was made possible by our fully-integrated site in France, where R&D laboratories, GMP manufacturing, quality control, and regulatory expertise are brought together under one roof. Such integration allows us to support our clients seamlessly throughout their product development journey, from early innovation through to global commercialization.Also, the inauguration of our new sterile hyaluronic acid production unit expands the possibilities for our HA to be used in advanced formulations with thermo-sensitive active ingredients, while upholding the uncompromising quality that defines HTL Biotechnology.Our operations are guided by internationally recognized standards, including ISO 13485 certification, which ensures the quality and safety required by medical device manufacturers worldwide.In addition, our Halal certification provides our customers with a significant advantage in accessing and expanding into markets where these requirements are essential for commercialization.Beyond certifications, our commitment to supporting global growth is reflected in the Drug Master Files we maintain across five continents, enabling our clients to accelerate product registration and bring innovative therapies to markets across the world more efficiently. By combining craftsmanship with pharmaceutical rigor, supported by state-of-the-art equipment and advanced bio-production methods, we ensure that every batch produced not only meets the strictest standards, but also delivers the reliability and consistency needed across the entire healthcare ecosystem. HIGHLIGHTS// Biopolymers with unmatched purity/record of no batch recalls/integrated facility in France/operations guided by global standards/new sterile HA unit for advanced formulations  Navigating the complex and evolving regulatory frameworks across global markets can be challenging for healthcare companies. Can you tell us more about how HTL Biotechnology supports its partners in this area? Regulatory support is part of our core premium services offer. We provide pharmaceutical regulatory support to ensure products meet the necessary compliance standards, so our partners can focus on their growth. Our dedicated regulatory professionals bring global and regional expertise, with a team specifically supporting customers in Asia. We offer personalized assistance adapted to their products and to the compliance standards of the target market. This includes personalized case-management support for regulatory file submissions with the concerned health authorities to minimize risks of refusal or delay, with the aim of achieving approval quickly and smoothly.Our offer for regulatory support continues beyond approval. We continuously monitor updates to regulations and provide post-commercialization support to our partners to help them manage any necessary regulatory updates.HIGHLIGHTS// Regulatory support offered as premium service/global and regional expertise/personalized case management for faster approvals/continuous regulatory support  How does HTL Biotechnology integrate sustainability and corporate responsibility into its operations? Sustainability is embedded in HTL Biotechnology’s strategic vision and day-to-day operations. In 2024, the company renewed its commitment to environmental responsibility by reinforcing its corporate social responsibility (CSR) roadmap. Tangible progress was made across multiple fronts: a 27 percent reduction in greenhouse gas emissions per kilogram of HA produced between 2021 and 2024, and a 34 percent reduction in water consumption per kilogram of HA since 2020. In 2024, we renewed the ISO 14001:2015 certification for its environmental management system, reflecting rigorous audit protocols and continual improvement cycles. All employees have been trained in the ISO 14001-certified environmental management system, and 78 percent of critical suppliers have signed HTL Biotechnology’s Responsible Purchasing Charter.These results reflect HTL Biotechnology’s structured and proactive approach to reducing its environmental footprint while maintaining the highest standards of quality and compliance.HIGHLIGHTS// Sustainability embedded in strategic vision/strong CSR roadmap with measurable progress/reduction in greenhouse gas emissions/responsible sourcing 

    Impressions: 2182

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/over-500-million-syringes-of-our-hyaluronic-acid-have-been-safely-used-worldwide

    PharmaCompass
    04 Nov 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaYour API, Our ExpertiseYour API, Our Expertise

    Your API, Our Expertise
    Your API, Our Expertise

    reelYour API, Our Expertise

    This PharmaReel showcases Minakem as a trusted partner for APIs, HPAPIs and steroids from FDA/GMP-certified sites, offering generic & custom solutions and CDMO services from lab to commercial supply, backed by regulatory know-how.

    Impressions: 365

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    Excipient Market Overview: Evonik launches high-purity excipients; India mandates disclosures from March 2026

    The global pharmaceutical excipients market continued to evolve in the third quarter (Q3) of 2025, supported by rising demand for functional excipients, growth in production of generics, and advances in drug delivery technologies. The global market for pharmaceutical excipients was estimated at US$ 9.8 billion to US$ 10.7 billion in 2024, and is projected to grow at a compound annual growth rate (CAGR) of 4.1 to 6.6 percent through 2030. At this pace, the market is expected to reach US$ 13.05 billion to US$ 14.86 billion by 2030. Europe retained the largest market share in 2024, followed by Asia-Pacific. Key drivers shaping the excipients market include the rising prevalence of chronic diseases, expansion of biologics and biosimilars, and increasing quality and regulatory expectations. Increased investments in facility expansions and ongoing reforms in clinical trial regulations are also facilitating market growth. The sector remains highly competitive and fragmented. Major excipient providers include BASF, Roquette, Gangwal Healthcare, DuPont, Evonik, Seqens, SPI Pharma, PMC Isochem, Croda International, Pfanstiehl, Colorcon, Kewpie Corporation, ICE Pharma, Nanjing Well Pharmaceutical, Merck KGaA owned MilliporeSigma, Minakem, Ashland Global, Actylis and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)  Evonik in partnership with Ethris; Colorcon Ventures invests in Phytolon   The market saw strategic collaborations across the excipients and drug formulation ecosystem in Q3 2025. Evonik entered into a partnership with Ethris to strengthen its nucleic acid delivery platform. The collaboration integrates Ethris’ proprietary technology — its lipidoid nanoparticle platform, known as SNaP LNP — into Evonik’s CDMO offerings, enhancing the latter’s ability to support RNA-based therapeutics from concept to clinic. Colorcon Ventures, the investment arm of Colorcon, announced a strategic investment in Israel-based Phytolon. The biotechnology start-up uses precision fermentation to develop natural colorants. The investment underscores Colorcon’s commitment to next-generation coloring technologies that support cleaner-label formulations and innovation in oral solid dosage coatings.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Evonik launches MaxiPure Polysorbate 80; Asahi Kasei expands its portfolio The quarter saw continued innovation in high-purity and injectable-grade excipients. Evonik introduced MaxiPure Polysorbate 80, a high-purity injectable-grade surfactant designed for biologics and parenteral formulations. This excipient addresses key challenges such as protein stability, viral inactivation, and the solubilization of hydrophobic APIs, while meeting regulatory expectations across global markets. Asahi Kasei expanded its Sonanos portfolio of excipients with two new products — Sonanos PG (optimized for sustained release of biologics and peptides while supporting patient-friendly dosing)  and Sonanos DS (developed to enhance solubility of poorly water-soluble APIs). These additions reflect growing industry demand for dosage optimization, stability, and specialized delivery of complex molecules. Gangwal Healthcare operates EXCiPACT-certified GMP facilities and offers a broad range of functional excipients, including co-processed blends like ProBlend, Starlose, and Microlose. Its excipients, including Solvostar (sodium starch glycolate) and Sallyso (croscarmellose sodium), support enhanced tablet disintegration and drug release. The company also provides taste-masking agents such as SucreX (sucralose) and CutCal (neotame), supporting the development of patient-friendly oral dosage forms.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Colorcon, Gattefossé, Croda, Roquette, Clariant expand manufacturing capacities Manufacturing investments and facility expansions remained a key trend during Q3 2025. Colorcon inaugurated a new state-of-the-art, film coating manufacturing facility in Johor, Malaysia. The site incorporates energy-efficient systems and advanced production technologies to strengthen Colorcon’s functional-excipient supply network across Asia. Gattefossé opened a new lipid-based excipient facility in Texas (US), marking a strategic expansion of its North American manufacturing footprint. Croda International expanded its Leek, UK facility with a lipid system synthesis unit and enhanced R&D capabilities. The site will support the launch of Super Refined Poloxamer 188, a highly purified fast-dissolving granular excipient. Roquette announced the opening of a dedicated innovation center in São Paulo, Brazil, strengthening its engagement with regional drug developers. Clariant expanded its Daya Bay, China facility, adding a second spray tower dedicated to pharmaceutical excipient production. The upgraded site increases capacity for excipients used in laxatives and other formulations. BASF also strengthened its commitment to biopharma and pharmaceutical ingredients with a new GMP Solution Center in Michigan (US). The facility expands BASF’s network of poloxamer (a synthetic polymer) manufacturing sites. With state-of-the-art clean room packaging and high-sensitivity analytical testing, this new facility will enable close collaboration with BASF’s customers on customized chemistries for product development.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   India mandates excipient disclosure; new rules to apply from March 2026  India has made it mandatory to disclose excipient details from March 2026 under the country’s new Drugs (2nd Amendment) Rules, 2025. This applies to Schedule H2 medicines. The final notification expands earlier draft requirements by mandating qualitative excipient details in QR codes on product packaging. This should enhance transparency and support patient safety. Meanwhile, US pharmaceutical groups have responded to the US Food and Drug Administration’s draft guidance proposing simplified pathways for replacing color additives in drug products. Industry associations have supported draft guidance, noting that it reduces regulatory burden while maintaining product quality and consistency.  View Our Dashboard on Major Excipient Companies in 2025 (Free Excel Available)   Our view While the fast-growing generics market is creating demand for cost-effective and versatile excipients, the market is also witnessing innovations tailored to the specialized needs of biologics and biosimilars. India is poised to become a key player in the global excipient market, supported by the rapid growth in its generic drug industry, expansion of its health infrastructure and increasing investments in R&D. The new excipient-disclosure rules, therefore, are likely to benefit the global excipient industry by improving transparency and strengthening quality ecosystems.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 429

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-evonik-launches-high-purity-excipients-india-mandates-disclosures-from-march-2026

    #PharmaFlow by PHARMACOMPASS
    20 Nov 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Jiuzhou Pharmaceutical Welcomes RayHua to Become a Group Member
    Jiuzhou Pharmaceutical Welcomes RayHua to Become a Group Member

    26 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/jiuzhou-pharmaceutical-welcomes-rayhua-to-become-a-group-member-301808047.html

    PR NEWSWIRE
    26 Apr 2023
    Share Share
    Novartis' spinoff-headed Sandoz sells Chinese plant for $15.1M
    Novartis' spinoff-headed Sandoz sells Chinese plant for $15.1M

    29 Sep 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/manufacturing/novartis-spinoff-headed-sandoz-sells-chinese-finished-drugs-plant-cdmo-jiuzhou-151m

    Angus Liu FIERCEPHARMA
    29 Sep 2022
    Share Share
    Novartis selling manufacturing site to Chinese drugmaker 
    Novartis selling manufacturing site to Chinese drugmaker 

    06 Sep 2019

    // Eric Palmer FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/novartis-selling-manufacturing-site-to-chinese-drugmaker

    Eric Palmer FIERCE PHARMA
    06 Sep 2019
    Share Share
    Indian Govt impose anti-dump duty on bulk drug import of Gliclazide from China
    Indian Govt impose anti-dump duty on bulk drug import of Gliclazide from China

    17 Dec 2015

    // TWOFOUR INSIGHT

    http://twofourinsight.com/indian-government-protects-local-pharma-industry-imposes-anti-dumping-duty-on-bulk-imports-from-china-of-gliclazide/

    TWOFOUR INSIGHT
    17 Dec 2015
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Carbamazepine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Carbamazepine

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 14893

    Submission : 2000-05-19

    Status : Inactive

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2002-221 - Rev 06

    Issue Date : 2019-02-05

    Type : Chemical

    Substance Number : 543

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 220MF10174

    Registrant's Address : Waisha Road 99, Jiaojiang, Taizhou City, Zhejiang, China 318000

    Initial Date of Registration : 2008-07-31

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65344-0028

    Start Marketing Date : 2019-07-16

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Ketoprofen

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Ketoprofen

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 23636

    Submission : 2010-03-16

    Status : Inactive

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2003-136 - Rev 08

    Issue Date : 2024-06-17

    Type : Chemical

    Substance Number : 922

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 225MF10157

    Registrant's Address : 18 Nan Yang San Road, Lin Hai City, Taizhou City Zhejiang Province

    Initial Date of Registration : 2013-08-14

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Sulfasalazine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Sulfasalazine

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 14724

    Submission : 2000-02-23

    Status : Inactive

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2002-088 - Rev 02

    Issue Date : 2015-03-20

    Type : Chemical

    Substance Number : 863

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 306MF10016

    Registrant's Address : Waisha Road 99# Jiaojiang Taizhou City, Zhejiang China

    Initial Date of Registration : 2024-01-24

    Latest Date of Registration :

    EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Medica Korea Co., Ltd.

    Registration Date : 2012-02-24

    Registration Number : 20091224-105-F-46-02(1)

    Manufacturer Name : Zhejiang Jizhou Pharmaceutical Co., Ltd.

    Manufacturer Address : 99 waisha Road, Jiaojiang District, Taizhou City, Zhejiang province, 318000, China

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Gefitinib

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Gefitinib

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-10-28

    Pay. Date : 2016-06-15

    DMF Number : 30518

    Submission : 2016-04-28

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2018-236 - Rev 02

    Issue Date : 2025-06-05

    Type : Chemical

    Substance Number : 2866

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65344-0029

    Start Marketing Date : 2023-12-29

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Gliclazide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Gliclazide

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2003-138 - Rev 01

    Issue Date : 2014-12-09

    Type : Chemical

    Substance Number : 1524

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 227MF10100

    Registrant's Address : Waisha Road 99# Jiaojiang Taizhou City, Zhejiang China

    Initial Date of Registration : 2015-04-09

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Imatinib Mesylate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Imatinib Mesylate

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 23343

    Submission : 2009-11-30

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2018-235 - Rev 02

    Issue Date : 2024-09-26

    Type : Chemical

    Substance Number : 2736

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65344-0020

    Start Marketing Date : 2024-12-30

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Venlafaxine Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Venlafaxine Hydrochloride

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-10-30

    Pay. Date : 2013-11-29

    DMF Number : 21195

    Submission : 2007-12-28

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2006-283 - Rev 00

    Issue Date : 2014-03-21

    Type : Chemical

    Substance Number : 2119

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65344-0017

    Start Marketing Date : 2011-08-03

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Meropenem

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Meropenem

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 27686

    Submission : 2013-11-01

    Status : Inactive

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 225MF10226

    Registrant's Address : No. 18, Nanyangsan Road, Linhai, Taizhou City, Zhejiang Province, P. R. China

    Initial Date of Registration : 2013-12-10

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Oxcarbazepine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Oxcarbazepine

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 20516

    Submission : 2007-05-03

    Status : Inactive

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2022-230 - Rev 02

    Issue Date : 2024-12-12

    Type : Chemical

    Substance Number : 2577

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Sulfadimethoxine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    CPhI India
    Not Confirmed
    arrow

    Sulfadimethoxine

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 15646

    Submission : 2001-08-13

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65344-0011

    Start Marketing Date : 2024-12-30

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    1-[2-amino-1-(4-methoxyphenyl) Ethyl...

    China
    CPhI India
    Not Confirmed
    arrow

    02

    10- Methoxy Iminostilbene (version N...

    China
    CPhI India
    Not Confirmed
    arrow

    03

    10-methoxy Iminostilbene

    China
    CPhI India
    Not Confirmed
    arrow

    04

    Atazanavir Sulfate

    China
    CPhI India
    Not Confirmed
    arrow

    05

    Atomoxetine Hydrochloride

    China
    CPhI India
    Not Confirmed
    arrow

    06

    Axitinib

    China
    CPhI India
    Not Confirmed
    arrow

    07

    Bck (4-nitrobenzyl(5r,6s)-6-[(1r)-1-...

    China
    CPhI India
    Not Confirmed
    arrow

    08

    Carbamazepine Usp

    China
    CPhI India
    Not Confirmed
    arrow

    09

    Clopidogrel Bisulfate

    China
    CPhI India
    Not Confirmed
    arrow

    10

    Darunavir

    China
    CPhI India
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Zhejiang Jiuzhou Pharmaceutical and get a quotation

    Zhejiang Jiuzhou Pharmaceutical is a supplier offers 73 products (APIs, Excipients or Intermediates).

    Find a price of Carbamazepine bulk with CEP, JDMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Ketoprofen bulk with CEP, JDMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sulfasalazine bulk with CEP, JDMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Gefitinib bulk with DMF, CEP offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Gliclazide bulk with CEP, JDMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Imatinib Mesylate bulk with DMF, CEP offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Venlafaxine Hydrochloride bulk with DMF, CEP offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Meropenem bulk with JDMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Oxcarbazepine bulk with CEP offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of 10- Methoxy Iminostilbene bulk with DMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Axitinib bulk with DMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Bezafibrate bulk with CEP offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Duloxetine Hydrochloride bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Gliclazide bulk with JDMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Molport-021-783-041 bulk with DMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Oxcarbazepine bulk with DMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sildenafil Citrate bulk with CEP offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sitagliptin Phosphate bulk with DMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sulfadimethoxine bulk with DMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sulfadimethoxine Sodium bulk with DMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Venlafaxine Hydrochloride bulk with DMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of LCA45 bulk with DMF offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of 10- Methoxy Iminostilbene bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Albendazole bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Atazanavir Sulfate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Atomoxetin Hydrochloride bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Clopidogrel bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Cyclohexanol bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Darunavir bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Erlotinib Hydrochloride bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of N-Methylparoxetine bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Nilotinib bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Paroxetine Hydrochloride bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Pregabalin bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Rivastigmine bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Rivastigmine Tartrate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Rufinamide bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sorafenib bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sulfasalazine bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Surecn2062622 bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Unii-269Gqp5C4X bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Venlafaxine bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of TRANS-(-)-PAROXOL bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Abacavir bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Acyclovir bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Amprolium bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Apixaban bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Atenolol bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Avibactam Sodium bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Baloxavir Marboxil bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of CAS 654671-77-9 bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Cilostazol bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Dapagliflozin bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Dapagliflozin Propanediol Monohydrate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Dexketoprofen Trometamol bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Edoxaban Tosylate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Ketoprofen Lysinate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Lacosamide bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Lenalidomide bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Loxoprofen Sodium bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Mirogabalin Besylate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Nirmatrelvir bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Rasagiline Mesylate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Ribociclib bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Rimegepant Sulfate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sacubitril Sodium bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sacubitril-Valsartan bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Semaglutide bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sitagliptin Hydrochloride bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Sulfadimethoxine bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Tenofovir Disoproxil Succinate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Vonoprazan Fumarate bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Find a price of Vortioxetine Hydrobromide bulk offered by Zhejiang Jiuzhou Pharmaceutical

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search